[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"narcolepsy-type-1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:narcolepsy-type-1":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,65,96,109,133,156,177,208,232,262,283,305,334,357,378,400,421],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100053299","phase-2-a-study-to-investigate-the-effects-of-cleminorexton-compared-with-placebo-in-the-treatment-of-participants-with-central-disorders-of-hypersomnolence-100053299",false,"NCT07598708","A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence","A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence","Key Inclusion Criteria:\n\n* 18-70 years of age\n* Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg\u002Fm\\^2 (inclusive)\n* Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria\n* Is willing and able to discontinue all medications used for the treatment of narcolepsy\n* Is willing and able to adhere to additional protocol requirements\n\nKey Exclusion Criteria:\n\n* Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)\n* Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease","ALL","18 Years","70 Years",{"count":20,"type":21},222,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \\[EDS\\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.\n\nWhile all conditions result in feeling sleepy, there are some differences in other common symptoms:\n\n* NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.\n* NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.\n\nOrexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.",[28,29],"Narcolepsy Type 1","Narcolepsy Type 2",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,28,29,47,48,49,50,51],"NT1","NT2","Excessive Daytime Sleepiness","Orexin Receptor 2 agonist","Central Disorders of Hypersomnia","Disorders of Excessive Somnolence","Dyssomnias","Nervous System Diseases","Mental Disorders","Hypersomnia","Hypersomnolence","Sleep Wake Disorders","Sleep Disorder","Sleep","Sleepiness","Cataplexy","Orexin","ORX750","Cleminorexton","Narcolepsy","SAPPHIRE","RECRUITING","2026-07-09",{"date":55,"type":56},"2026-07-13","ACTUAL",{"date":58,"type":56},"2026-05-29",{"date":60,"type":21},"2027-12-31",{"name":62,"class":63},"Centessa Pharmaceuticals (UK) Limited","INDUSTRY",7,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100627957","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-alks-2680-in-adults-with-narcolepsy-type-1-100627957","NCT07455383","A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 302)","Brilliance NT1","Inclusion Criteria:\n\n* Meets the diagnostic criteria of NT1 according to ICSD-3-TR guidelines, confirmed by diagnostic evaluations (either PSG\u002FMSLT\\* or CSF hypocretin-1 level).\n\nExclusion Criteria:\n\n* Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle.\n* Has a history or presence at Visit 1 of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise participant safety, interfere with any study assessment, or affect the participant's ability to complete the study.\n* Is currently enrolled in another interventional clinical trial or has received any investigational drug or used any interventional investigational device within 30 days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-201 are not eligible for enrollment.\n* Is currently pregnant, breastfeeding, or is planning to become pregnant during the study",{"count":74,"type":21},150,[25],"The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.",[28],[79,50,28,80,81,46,82,83,84,85],"Brillance","Sleep Disorders","Fatigue","ALKS 2680","Alixorexton","Orexin-2 receptor agonist","excessive daytime sleepiness","2026-06-30",{"date":88,"type":56},"2026-07-02",{"date":90,"type":56},"2026-04-06",{"date":92,"type":21},"2027-06",{"name":94,"class":63},"Alkermes, Inc.",22,{"id":97,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":26,"conditions":100,"keywords":101,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":107,"locationsCount":108},"100642941",{"count":20,"type":21},[24,25],[28,29],[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,28,29,47,48,49,50,51],"2026-06-29",{"date":104,"type":56},"2026-07-01",{"date":58,"type":56},{"date":60,"type":21},{"name":62,"class":63},5,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100643019","phase-2-a-study-of-tak-360-in-adults-with-narcolepsy-type-1-narcolepsy-with-cataplexy-100643019","NCT07633301","A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)","A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)","Key Inclusion Criteria:\n\n1. The participant has a body mass index within the range 18 to 40 kilograms per meter square (kg\u002Fm\\^2) (inclusive).\n2. The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or ICSD-3 Text Revision diagnosis of NT1.\n\nKey Exclusion Criteria:\n\n1. The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with excessive daytime sleepiness.\n2. The participant: (a) has a history of myocardial infarction; (b) has a history of clinically significant thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure.\n3. The participant has a clinically significant history of head injury or head trauma.\n4. The participant has a history of epilepsy, seizure, or convulsion (except for a single febrile seizure in childhood).\n5. The participant has a history of cerebral ischemia, transient ischemic attack (\\\u003C5 years from screening), intracranial aneurysm, or arteriovenous malformation.\n6. The participant has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without further treatment or basal cell carcinoma; these participants may be included after approval by the medical monitor).\n7. The participant has a positive test result for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, or human immunodeficiency virus (HIV) antibody\u002Fantigen at screening.\n8. The participant plans to participate in any other interventional trial while participating in TAK-360-2004 or has previously participated in another part in TAK-360-2004.\n9. The participant has a known hypersensitivity to any component of the formulation of TAK-360 or related compounds.",{"count":117,"type":21},92,[24],"Narcolepsy is a sleep disorder that disrupts a person's regular sleep-wake cycle. It causes extreme sleepiness during the day (called excessive daytime sleepiness \\[EDS\\]), where a person may fall asleep without warning. Narcolepsy Type 1 (NT1) is a form of the condition in which people also have sudden, unexpected muscle weakness while staying conscious (called cataplexy).\n\nThe main aim of this study is to learn how safe TAK-360 is and how well adults with NT1 tolerate it. Adults who can participate in the study will have to stop taking their existing medicines for NT1 before study treatment starts. Participants may be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo during the treatment period. The placebo looks just like TAK-360 but does not have any medicine in it. After the treatment period, participants can be monitored for another 2 weeks. Participants can restart their usual NT1 treatment after study treatment ends.\n\nThe participants will have to visit the clinic multiple times during this study.",[28],[122,123,31],"Drug Therapy","Narcolepsy With Cataplexy","2026-06-26",{"date":102,"type":56},{"date":127,"type":56},"2026-06-04",{"date":129,"type":21},"2027-11-28",{"name":131,"class":63},"Takeda",18,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},"100642659","phase-2-a-study-of-tak-360-in-people-with-narcolepsy-or-idiopathic-hypersomnia-100642659","NCT07646678","A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia","A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants With Selected Central Hypersomnia Conditions","Key Inclusion Criteria:\n\n1. Participant is willing and able to understand and fully comply with trial procedures and requirements.\n2. Participant has a confirmed diagnosis of either NT1, NT2, or IH, and has completed the treatment period of a parent TAK-360 trial.\n3. Participant has provided informed consent (that is, in writing, documented via a signed and dated informed consent form (ICF) and any required privacy authorization before the initiation of any trial procedures.\n\nKey Exclusion Criteria:\n\n1. Participant has a positive pregnancy test or is lactating\u002Fbreastfeeding.\n2. Participant has a risk of suicide according to endorsement of item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).\n3. The participant has developed a new medical disorder associated with excessive daytime sleep (EDS).\n4. Participant has developed (within the last 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.\n5. Participant has developed a new history of seizures.\n6. Participant has experienced clinically significant head injury, per investigator opinion.\n7. Participant has developed a history of cerebral ischemia, transient ischemic attack (less than \\[\\\u003C\\] 5 years ago), or cerebral haemorrhage.\n8. Participant has developed a history of myocardial infarction, clinically significant coronary artery disease, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure.\n9. The participant has been diagnosed with medically significant thyroid disease, known functional hepatic impairment, or other severe chronic medical condition other than the central hypersomnolence disorder.\n10. Participant has developed a history of cancer in the past 5 years.","71 Years",{"count":142,"type":21},500,[24,25],"Central hypersomnia conditions are a group of sleeping disorders where the brain has trouble keeping a person awake during the day (called excessive daytime sleepiness or EDS). These conditions usually include narcolepsy (type 1 and 2) and idiopathic hypersomnia (IH). Narcolepsy type 1 (NT1) includes sudden muscle weakness while you stay awake, called cataplexy, often triggered by strong emotions. Narcolepsy type 2 (NT2) does not include cataplexy. People with narcolepsy typically feel refreshed by short naps. People with IH feel extremely sleepy during the day, and do not feel refreshed by sleep. Waking up from sleep is difficult. This is common in the morning and also when waking up from long naps.\n\nThe study wants to learn about TAK-360 when taken over a long time period; this is called a long-term extension or LTE study. The main aim of this LTE study is to find out how well participants with NT1, NT2, and IH tolerate TAK-360 over a longer period (long-term tolerability) and to learn how safe TAK-360 is when given over a longer period of time (long-term safety).\n\nParticipants who completed one of the TAK-360 parent studies can join this study if they meet the study rules. Parent studies include TAK-360-2001(NCT06952699), TAK-360-2002 (NCT06812078), or other TAK-360 studies that evaluate the TAK-360 medicine. All participants will receive TAK-360 in this study. They will either receive the same dose as they did in the parent study, or the closest dose available in this LTE study. Participants who received placebo (the placebo looks just like TAK-360 but does not have any medicine in it) in their parent study will receive one of the TAK-360 doses available in this study. Placebo will only be used to not reveal the dose of TAK-360 from parent studies to investigator, participants, and sponsor. Sponsor, investigators and participants will not know which TAK-360 dose was used in the LTE study as long as the parent study is ongoing.\n\nThe participants will have to visit the clinic multiple times during this study.",[146,28,29],"Idiopathic Hypersomnia",[122],"2026-06-25",{"date":86,"type":56},{"date":151,"type":56},"2026-06-11",{"date":153,"type":21},"2031-06-15",{"name":131,"class":63},1,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":76,"conditions":165,"keywords":166,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":108},"100634531","phase-3-a-study-to-evaluate-the-efficacy-safety-and-tolerability-of-alks-2680-in-adults-with-narcolepsy-type-1-brilliance-nt1---304-100634531","NCT07540897","A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 304)","Inclusion Criteria:\n\n* Meets the diagnostic criteria of NT1 according to ICSD-3-TR guidelines, confirmed by diagnostic evaluations (either PSG\u002FMSLT\\* or CSF hypocretin-1 level)\n\nExclusion Criteria:\n\n* Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle.\n* Has a history or presence at Visit 1 of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise participant safety, interfere with any study assessment, or affect the participant's ability to complete the study.\n* Is currently enrolled in another interventional clinical trial or has received any investigational drug or used any interventional investigational device within 30 days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-201 are not eligible for enrollment.\n* Is currently pregnant, breastfeeding, or is planning to become pregnant during the study.",{"count":74,"type":21},[25],[28],[28,31,83,45,167,84,168,85],"Orexin-2","sleep disorder","2026-06-15",{"date":171,"type":56},"2026-06-16",{"date":173,"type":21},"2026-06",{"date":175,"type":21},"2027-07",{"name":94,"class":63},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":184,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":207},"100553304","deciphering-the-interactions-between-food-intake-sleepiness-and-nighttime-sleep-quality-in-patients-with-type-1-narcolepsy-and-idiopathic-hypersomnia-100553304","NCT06484348","Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia","NARCOFOOD","Inclusion Criteria :\n\n* Patients with NT1 or IH (ICSD-3-TR) or Healthy Controls without sleep disorder\n* Familiar use of a smartphone\n\nExclusion Criteria :\n\n* Untreated moderate or severe sleep apnea syndrome;\n* Cognitive disorders incompatible with the protocol;\n* Unstable treatment or treatment with sodium oxybate;\n* Unstable medical or psychiatric pathology;\n* Shift work;\n* Pregnancy or breastfeeding;\n* Diabetes",true,"65 Years",{"count":187,"type":21},76,[189],"NA","Links between sleep and food intake are manyfold. In healthy individuals, sleep deprivation promotes obesity by stimulating food intake of high glycemic index (GI) foods. Conversely, high GI foods induce sleepiness. Obesity is observed in 30-50% of patients with Narcolepsy type 1 (NT1). Its determinism may involve transient changes in basal metabolism at the early stage of the disease, eating disorders, disrupted nighttime sleep and sleepiness. In contrast, patients suffering from idiopathic hypersomnia (IH), whose nocturnal sleep is generally long and of good quality, rarely present with obesity. By studying the relationships between diet, body composition and sleep patterns in these two populations and in healthy controls, the NARCOFOOD study aims to provide a better understanding of the determinants of obesity in narcolepsy and, more generally, of the effects of food intake on sleepiness.\n\nPatients will be recruited at the Lyon and Clermont-Ferrand sleep centers and Controls at the Lyon Neuroscience Research Center or through communications to the general public. Data from clinical evaluation (including body mass index and body composition), and questionnaires (sleep quality, insomnia, sleepiness, anxiety and depression, impulsivity, eating behaviors) will be collected. During 4 days, at home, the following parameters will be explored : 1) eating behaviors (meals' photos) and sugar consumption (FreeStylePro sensor measuring interstitial glucose) 2) sleep\u002Fwake rhythm (diary and actigraphy) 3) nocturnal sleep parameters (Somfit device) 4) sleepiness (Karolinska sleepiness scale and EEG markers of sleepiness with the Somfit device) before and after meals.\n\nThe hypothesis is that increased sleepiness would favor food intake of high GI foods, which would worsen sleepiness in all 3 groups, with a more pronounced effect in NT1. Compared to IH patients and controls, NT1 patients may present more snacking of high GI foods, especially at night if sleep is disrupted, and this would be correlated with body composition.\n\nThe findings will help to better understand the mechanisms of obesity in narcolepsy and may lay the ground for the development of new therapeutic strategies in disorders of hypersomnolence, targeting dietary behaviors.",[28,146],[193,146,194,195,196],"Narcolepsy type 1","Obesity","Food intake","Disrupted nighttime sleep","2026-06-01",{"date":199,"type":56},"2026-06-03",{"date":201,"type":56},"2024-10-16",{"date":203,"type":21},"2027-07-16",{"name":205,"class":206},"Hospices Civils de Lyon","OTHER",2,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":218,"phases":4,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":231},"100615937","epidemiology-of-narcolepsy-type-1-and-type-2-in-spain-100615937","NCT07299097","Epidemiology of Narcolepsy Type 1 and Type 2 in Spain","HYPNOS","\\- Core Group:\n\nInclusion Criteria:\n\n1. Participants with NT1 or NT2 following International Classification of Sleep Disorders, 3rd Edition (ICSD-3) or ICSD-3 text revision (ICSD-3-TR) criteria who are alive at any point during 2023 or 2024.\n2. Any age, ethnicity and nationality.\n3. Treated \u002F under follow-up in the study site and residing in the hospitals' reference areas. Consideration will be given if participants have changed their address or reached adulthood.\n\nExclusion Criteria\n\n1\\. NT1 or NT2 participants who do not reside in the hospitals' reference areas.\n\n\\- Supplementary Group:\n\nInclusion criteria:\n\n1. Confirmation to have a diagnosis of NT1 or NT2 by a specialist.\n2. Participants greater than equal to (≥) 18 years or parents of narcolepsy participants under 18 years of age.\n3. Any gender, ethnicity or nationality.\n4. Residence in Spain.\n\nExclusion criteria:\n\n1\\. Participants without a confirmed NT1 or NT2 diagnosis by a specialist.","0 Years",{"count":217,"type":21},100,"OBSERVATIONAL","The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year. Narcolepsy is a rare sleep disorder that causes excessive daytime sleepiness. The researchers will look at medical records from hospitals across Spain to count participants with these conditions and understand patterns in diagnosis over time.",[28,29],[222],"Drug therapy","2026-05-12",{"date":225,"type":56},"2026-05-15",{"date":227,"type":56},"2025-12-02",{"date":229,"type":21},"2026-07-31",{"name":131,"class":63},10,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":155},"100621049","pain-assessment-in-patients-with-idiopathic-rapid-eye-movement-rem-sleep-behaviour-disorder-100621049","NCT07365566","Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder","Pain Assessment in Patients With Idiopathic REM Sleep Behaviour Disorder","PAIN-iRBD","Inclusion criteria:\n\n* Diagnosed with iRBD confirmed by polysomnography;\n* No clinical diagnosis of Parkinson's disease or other diagnosis of neurodegenerative disease;\n* Ability to understand and complete study procedures and questionnaires;\n\nControl group:\n\n* Diagnosed with narcolepsy type 1;\n* Coexisting REM sleep behavior disorder confirmed by polysomnography;\n* Ability to understand and complete study procedures and questionnaires;\n\nExclusion Criteria:\n\n* Diagnosed Parkinson's Disease, dementia with Lewy bodies or multiple system atrophy;\n* Severe depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM V);\n* Inability to complete study procedures or questionnaires.",{"count":241,"type":21},24,[189],"Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, with over 12 million patients expected globally by 2040. The disease is currently diagnosed at the appearance of motor symptoms, but by then, over 60% of striatal dopaminergic neurons have already been destroyed. Prodromal symptoms such as idiopathic REM Sleep Behavior Disorder (iRBD), anosmia, mood disorders and constipation appear earlier and are listed as criteria for a prodromal PD diagnosis. Identifying early signs is critical to initiate neuroprotective treatments as early as possible. While pain is prevalent and highly disabling in early PD, no data are currently available on pain perception in iRBD patients, whose condition is of the main risk factor for PD development.",[245,28],"REM Sleep Behavior Disorder (iRBD)",[247,248,249,250,251,252],"parkinson","REM sleep","pain","REM sleep behavior disorder","narcolepsy Type 1","sleep","2026-04-27",{"date":255,"type":56},"2026-05-01",{"date":257,"type":56},"2026-02-24",{"date":259,"type":21},"2026-08",{"name":261,"class":206},"University Hospital, Toulouse",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":282},"100573929","phase-2-a-study-of-orx750-in-participants-with-narcolepsy-and-idiopathic-hypersomnia-100573929","NCT06752668","A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia","A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1)","CRYSTAL-1","Inclusion Criteria:\n\n* 18-65 years of age\n* BMI ≥17 and ≤37 kg\u002Fm2\n* Meets the diagnostic criteria of Narcolepsy Type 1 (NT1), Type 2 (NT2) or Idiopathic Hypersomnia (IH) according to ICSD-3-TR criteria\n* Is willing and able to discontinue all medications used for the treatment of narcolepsy or idiopathic hypersomnia\n* Is willing and able to adhere to additional protocol requirements\n\nExclusion Criteria:\n\n* A medical disorder other than NT1, NT2, or IH that is associated with excessive daytime sleepiness (EDS).\n* Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease",{"count":271,"type":21},248,[24],"Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \\[EDS\\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.\n\nWhile all conditions result in feeling sleepy, there are some differences in other common symptoms:\n\n* NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.\n* NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.\n* IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up.\n\nOrexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton (also known as ORX750) is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.",[28,29,146],"2026-04-22",{"date":253,"type":56},{"date":278,"type":56},"2024-12-23",{"date":280,"type":21},"2026-12",{"name":62,"class":63},37,{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":241},"100600375","phase-2-a-long-term-extension-study-of-orx750-in-participants-with-narcolepsy-and-idiopathic-hypersomnia-100600375","NCT07096674","A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia","A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial","Inclusion Criteria:\n\n* Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1)\n* Is willing and able to adhere to additional protocol requirements\n\nExclusion Criteria:\n\n* Development of any new disease\u002Fdisorder that in the opinion of the investigator would make the participant unable to continue the study\n* Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia",{"count":291,"type":21},90,[24],"This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).",[28,29,146],[31,32,296,50,28,29,146,33,34],"IH","2026-04-15",{"date":299,"type":56},"2026-04-16",{"date":301,"type":56},"2025-08-12",{"date":303,"type":21},"2026-04-30",{"name":62,"class":63},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":324,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":155},"100545584","decreasing-nightmares-in-adults-with-narcolepsy-100545584","NCT06383806","Decreasing Nightmares in Adults With Narcolepsy","Imagery Rehearsal Therapy for the Treatment of Nightmares in Narcolepsy: A Pilot Randomized Controlled Trial","DAWN","PARTICIPANTS WITH NARCOLEPSY\u002FNIGHTMARES\n\nInclusion Criteria:\n\n* Diagnosis of narcolepsy type 1 or narcolepsy type 2\n* Nightmare frequency of ≥1 times per week\n* Age 18 or older\n* Able to speak, read, and write in English\n* Live in the United States\n* Sleep and psychiatric medications stable for ≥ 1 month and willing to keep medications stable for the duration of the study\n\nExclusion Criteria:\n\n* Currently engaged in trauma- or sleep-related psychotherapy\n* Previous behavioral treatment for nightmares\n* Medical, psychiatric, or cognitive condition which would interfere with ability to engage in the treatment\n* Untreated moderate-severe sleep apnea\n\nPARTICIPANTS WHO ARE PARTNERS OF SOMEONE WITH NARCOLEPSY\n\nInclusion Criteria:\n\n* Live with a romantic partner who meets the above criteria and has agreed to participate in the study\n* Age 18 or older\n* Able to speak, read, and write in English\n* Live in the United States",{"count":314,"type":21},80,[189],"The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with narcolepsy. All participants will receive the treatment and will complete three assessments. Half of the participants will receive the treatment after the first assessment, and half will receive it after the second assessment. Romantic partners of participants with narcolepsy will also be eligible to enroll in the study. Partners will complete three assessments but will not participate in the treatment.",[50,28,123,318,319,320],"Narcolepsy Without Cataplexy","Nightmare","Nightmare Disorder With Associated Other Sleep Disorder",[322,323],"Imagery Rehearsal Therapy","Cognitive Behavioral Therapy for Nightmares","NOT_YET_RECRUITING","2026-03-09",{"date":327,"type":56},"2026-03-10",{"date":329,"type":21},"2026-04-01",{"date":331,"type":21},"2027-09",{"name":333,"class":206},"University of Utah",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":343,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":356},"100575084","phase-2-a-long-term-study-of-alks-2680-in-subjects-with-narcolepsy-and-idiopathic-hypersomnia-100575084","NCT06767683","A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia","An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia","Inclusion Criteria:\n\n* Was eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3)\n* Is willing and able, and in the opinion of the treating physician can safely discontinue any medications prescribed for the management of narcolepsy symptoms, as applicable, for 5 half-lives prior to Day 1 (for re-entry subjects), and for the duration of study (for all subjects)\n\nExclusion Criteria:\n\n* Developed a new clinically significant health condition, ECG or laboratory abnormality, in the opinion of the Investigator or Sponsor, may impact the subject's participation in the study\n* Is currently pregnant, breastfeeding, or planning to become pregnant during the study\n* Is currently enrolled in another clinical study (other than the parent study) or used any investigational drug or device within 30 days prior to Screening",{"count":342,"type":21},256,[24,25],"The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.",[28,29,146],[50,28,29,31,32,347,252,168,85,296,146],"orexin-2 receptor agonist","2026-03-03",{"date":350,"type":56},"2026-03-04",{"date":352,"type":56},"2025-01-27",{"date":354,"type":21},"2028-06",{"name":94,"class":63},46,{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":364,"maxAge":18,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":377},"100501986","phase-2-a-study-of-tak-861-for-the-treatment-of-selected-central-hypersomnia-conditions-100501986","NCT05816382","A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions","A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions","Inclusion criteria:\n\n1\\. Participant with a diagnosis of NT1 who has completed a controlled trial with TAK-861, and for whom the investigator has no clinical objection to their enrollment.\n\nExclusion criteria:\n\n1. Participant has a treatment-emergent adverse event (TEAE) that remains severe at the time of rollover related to the trial intervention from the parent trial or discontinued because of TEAEs in the parent trial.\n2. Participant has a risk of suicide according to endorsement of item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).\n3. The participant has alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values greater than (\\>) 1.5 times the upper limit of normal (ULN).\n4. Participant has a current medical disorder, other than narcolepsy with or without cataplexy, associated with excessive daytime sleepiness (EDS).\n5. Participant has current active major depressive episode (MDE) or has had an active MDE in the past 6 months.\n6. Participant has developed (within the last 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.\n7. Participant has epilepsy or history of seizure.\n8. Participant has any other medical condition, such as anxiety, depression, heart disease, or significant hepatic, pulmonary, or renal disease, that requires them to take excluded medications.\n9. Participant has a history of cerebral ischemia, transient ischemic attack (less than (\\\u003C) 5 years ago), or cerebral hemorrhage.\n10. Participant has a history of myocardial infarction, clinically significant coronary artery disease, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure.\n11. Participant has a history of cancer in the past 5 years.","16 Years",{"count":142,"type":21},[24,25],"The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.",[28],[122],{"date":371,"type":56},"2026-03-05",{"date":373,"type":56},"2023-04-05",{"date":375,"type":21},"2028-02-28",{"name":131,"class":63},52,{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":184,"sex":16,"minAge":386,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":218,"phases":4,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":398,"locationsCount":207},"100538573","bacterial-translocation-and-gut-microbiota-in-type-1-narcolepsy-patients-versus-a-control-population-100538573","NCT06292598","Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population","Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients","NARCOBIOTE","Inclusion Criteria:\n\n* Patient diagnosed with narcolepsy type 1 (NT1).\n* Patient not treated for narcolepsy during initial evaluation of NT1 patients.\n* Patient eligible for treatment for longitudinal monitoring of NT1 patients.\n* Patient speaking and understanding French.\n* The patient must have given their free and informed consent and signed the consent form or consent has been provided from the holder(s) of parental authority or the legal guardian and the child.\n* The patient must be a member or beneficiary of a health insurance plan\n\nInclusion criteria for control subjects:\n\n• Absence of diagnosis of sleep disorder responsible for hypersomnolence with an Epworth sleepiness scale score greater than 10\u002F24.\n\nExclusion Criteria:\n\n* Subject having presented an infectious pathology requiring antibiotic treatment in the previous 3 months.\n* Subject with a dysimmune pathology.\n* Subject having had treatment with an immunomodulatory molecule or chemotherapy within 60 days before inclusion in the research or whose indication is planned for the duration of the research.\n* Subject with a chronic digestive pathology or having undergone bariatric surgery in the previous year.\n* Subject on laxative.\n* Subject living in a medical institution.\n* Subject under legal protection, guardianship or curatorship.\n* Subject and\u002For their legal representative (if a minor patient) unable to express consent\n* Taking antibiotics during the inclusion period, or laxative or any other treatment having a significant impact on the microbiota","10 Years",{"count":388,"type":21},120,"Narcolepsy type 1 (NT1) is a rare disease characterized by severe drowsiness, cataplexy, hypnagogic hallucinations, sleep paralysis, poor night sleep, and often obesity. NT1 is caused by irreversible loss of orexin (ORX)\u002Fhypocretin neurons in the lateral hypothalamus with decreased ORX levels in the cerebrospinal fluid (CSF). Although the underlying process leading to this destruction remains unclear; an autoimmune origin is suspected.\n\nThe study authors recently compared the bacterial communities of the fecal microbiota of NT1 patients and control subjects. Initial results demonstrated a difference in overall bacterial community structure in NT1 compared to controls, as assessed by beta diversity, even after adjusting for body mass index (BMI). The Shannon biodiversity index was also correlated with the duration of NT1 disease. However, no association was found between the structure of the microbial community and the clinical characteristics of NT1 patients.\n\nIn 2022, a second study from the SOMNOBANK cohort on a larger population confirmed these results, showing dysbiosis between NT1 patients and the control population. The altered intestinal microbial diversity supports the important role of the environment in the development and pathogenesis of NT1. Other studies have established a link between dysbiosis, intestinal permeability and inflammation in other neuroimmune pathologies. Currently, no study has focused on these phenomena of bacterial translocation, intestinal permeability and immune activation linked to the microbiota in type 1 narcolepsy patients.\n\nThe study hypothesis is that NT1 patients with dysbiosis in their intestinal microbiota also present a bacterial translocation with an intestinal origin, leading to a systemic inflammatory syndrome favoring an autoimmune damage destroying hypocretin neurons in the hypothalamus. The study authors suspect that microbial elements (DNA) involved in the autoimmune process could be detected in the CSF. This bacterial translocation could vary over time depending on: i) the progression of the disease and its management; ii) changing dysbiosis and: iii) the increase in intestinal permeability and inflammation.",[28,391],"Bacterial Translocation","2025-11-14",{"date":394,"type":56},"2025-11-17",{"date":396,"type":56},"2025-03-10",{"date":331,"type":21},{"name":399,"class":206},"Centre Hospitalier Universitaire de Nīmes",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":155},"100551273","mind-wandering-and-predictive-processes-in-narcolepsy-a-putative-mechanism-through-covert-rem-intrusions-100551273","NCT06457945","Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions","Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions, the NarcoWandering Study","NARCOWANDERING","Inclusion Criteria:\n\n* Patients with NT1 or IH diagnosis according to ICSD3-TR criteria (American Academy of Sleep, 2023)\n* For patient with IH: with abnormal Mean Sleep Latency Test (MSLT) (mean latency ≤ 8 min, ≤ 1 SOREMp)\n* Patients with subjective hypersomnolence without underlying cause (negative extensive work-up including actigraphy, PSG, MSLT, 24h bedrest, biological tests, MRI, psychiatric consultation; this allows to rule out sleep deprivation, irregular sleep\u002Fwake schedule, sleep apnea or other sleep disorders associated with sleep fragmentation, somatic\u002Fpsychiatric causes of hypersomnolence, sedative substance intake). This type of \"controls\" have already been used in studies on hypersomnolence disorders.\n\nExclusion Criteria:\n\n* Cognitive impairment not compatible with the task\n* Treatment with antidepressant\n* Other cause of hypersomnolence: untreated severe obstructive sleep apnea, sleep-wake circadian rhythm disorders, sleep deprivation, somatic\u002Fpsychiatric causes of hypersomnolence, sedative substance intake\n* Unstable medical or psychiatric condition\n* Refusal to participate",{"count":409,"type":21},180,[189],"Mind wandering is a state in which attention turns away from the external environment or current task to focus on internal thoughts (past experiences, future events, planned actions...). Humans are thought to spend at least one third of their waking lives in this state. Mind wandering can be assessed experimentally by investigating mental content during well-controlled tasks. In this case, task-unrelated thoughts likely to arise during tasks of varying cognitive demand are studied. Mind wandering (=task-unrelated thoughts) has a deleterious effect on cognitive performance in most paradigms, particularly those requiring sustained attention and executive control. However, this phenomenon could also have cognitive benefits, although knowledge on this issue remains limited. For example, it has been suggested that mind wandering could promote creativity, anticipation of future scenarios and prospective memory. In a recent behavioural study, we investigated the cost and benefit of mind wandering in an implicit visual-motor probabilistic learning task (ASRT - Alternating Serial Reaction Time Task). ASRT distinguishes between two fundamental processes: visuomotor performance and implicit statistical learning. While the former reflects visuo-spatial discrimination efficiency, the latter refers to the unintentional acquisition of probabilistic regularities of external inputs. Reduced visuo-spatial accuracy and faster but less accurate responses have been observed during periods of mind-wandering. On the other hand, mind-wandering was associated with enhanced statistical learning reflecting improved predictive processing.\n\nWhereas the study of the neural correlates of mind-wandering is constantly growing, the mechanisms triggering mind-wandering are far from being unravelled, but may involve sleep pressure. Thus, the frequency of mind wandering tends to increase after sleep deprivation or during attention-demanding cognitive tasks, during which neurophysiological markers of local sleep appear. These markers of sleep during wakefulness are frequently observed in hypersomnolence disorders. They are generally defined by the appearance of slow waves (typical of slow wave sleep, SWS). Nevertheless, sleep intrusions during wakefulness may not be limited to non-rapid-eye-movement (NREM) sleep but also concern REM sleep. REM sleep is the sleep state when the most intense forms of dreaming occur, and could therefore be phenomenologically similar to the reverie of mind wandering. Thus, daytime mental wandering could be triggered by intrusions of REM sleep during wakefulness.\n\nPatients with narcolepsy type 1 (NT1) exhibit frequent REM sleep onset during daytime wakefulness. The study of ASRT in this population therefore offers a unique opportunity to investigate the role of REM sleep intrusions in mind wandering. The hypothesis is that mind wandering would be observed more frequently during the ASRT task in NT1 patients (with REM sleep intrusions during wakefulness) than in patients with idiopathic hypersomnia (IH) (with NREM sleep intrusions during wakefulness) and patients with subjective hypersomnolence (little or no sleep intrusion). Furthermore, it could be possible that REM sleep-related mind wandering would be associated with impaired visuomotor performance in terms of accuracy, but improved predictive processing (probabilistic learning) compared to NREM sleep intrusions or no sleep intrusion during the task.",[28,41,146],"2025-01-10",{"date":415,"type":56},"2025-01-13",{"date":417,"type":56},"2024-12-03",{"date":419,"type":21},"2026-12-03",{"name":205,"class":206},{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":218,"phases":4,"briefSummary":431,"conditions":432,"keywords":433,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":155},"100541914","mentalizating-in-adults-suffering-from-narcolepsy-type-1-100541914","NCT06336057","Mentalizating in Adults Suffering from Narcolepsy Type 1.","Mentalizating in Adults Suffering from Narcolepsy Type 1, a Comparative Prospective Study.","NARCOMENTAL","Inclusion Criteria:\n\nFor the NT1 patient group:\n\n* Adult patient having been diagnosed with type 1 narcolepsy according to ICSD 3 criteria and the completion of a 48-hour polysomnography at the Sleep Laboratory\n* Patient affiliated to or beneficiary of a social security system\n\nFor the control group:\n\n* Patient over 18 years old\n* Patient followed at Toulouse University Hospital and treated for Obstructive sleep apnea (OSA) with a residual AHI \\\u003C5\u002Fh, demonstrating the absence of residual OSA under treatment\n* Patient affiliated to or beneficiary of a social security system\n\nExclusion Criteria:\n\n* Patient with a history of autism spectrum disorder, chronic psychotic disorder, or bipolar disorder.\n* Patient with a history of cognitive disorders of neurological origin\n* Patient with a linguistic level in French that does not allow sufficient understanding to complete the questionnaires\n* Patient under legal protection measure, under guardianship or curatorship\n* Pregnant or breastfeeding woman",{"count":430,"type":21},60,"The main objective is to examine the potential mentalization impairments affecting a population suffering from narcolepsy type 1. Indeed, the hypothesis of this research is that mentalization could be impaired in narcoleptic patients.",[28],[193,434,435,436],"Mentalization","Reflective functioning questionnaire","Mental states task","2024-09-23",{"date":439,"type":56},"2024-09-25",{"date":441,"type":56},"2024-05-17",{"date":443,"type":21},"2025-12",{"name":261,"class":206}]